- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07584122
Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro
Bringing PrEP to Underserved Communities in Rio de Janeiro: the PrEPOUT Rio Study
This study aims to improve access to HIV prevention using pre-exposure prophylaxis (PrEP) among underserved populations in Rio de Janeiro, including gay and bisexual men, transgender women, and sex workers. Despite the proven effectiveness of PrEP, many people at higher risk of HIV face barriers to accessing and continuing this prevention method, especially those living in socially and economically vulnerable communities.
The study will evaluate whether offering PrEP directly in community-based settings-such as non-governmental organizations, mobile health units, and through telehealth and digital tools-can increase its uptake and continued use. Participants who test negative for HIV will be offered daily oral PrEP, along with counseling and follow-up support. Those who test positive will be referred for appropriate treatment.
The main hypothesis is that delivering PrEP in community settings, combined with supportive strategies like mobile health interventions, will be feasible, acceptable, and more effective in reaching and engaging vulnerable populations, ultimately helping to reduce new HIV infections.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The PrEPOUT Rio Study is designed to evaluate the implementation of community-based strategies to expand access to and engagement with oral pre-exposure prophylaxis (PrEP) for HIV prevention among underserved populations in Rio de Janeiro and the metropolitan area, including Nova Iguaçu. The study focuses on populations disproportionately affected by HIV, such as gay, bisexual, and other men who have sex with men (MSM), transgender women, other sexual and gender minorities, and sex workers.
The study will be conducted in three phases. The formative phase will use qualitative methods, including focus group discussions with key stakeholders and members of the target population, to identify barriers and facilitators to PrEP uptake and to inform the adaptation of community-based delivery strategies.
In the implementation phase, PrEP will be offered in non-traditional settings, including community-based organizations and mobile health units, aiming to reduce structural and social barriers to access. Trained healthcare staff will provide on-site HIV testing, counseling, and PrEP initiation. Participants who test HIV-negative will be offered daily oral PrEP, while those diagnosed with HIV will be promptly referred for treatment within the public health system. The study will also incorporate supportive strategies such as telehealth consultations and mobile health (mHealth) interventions to enhance adherence, retention, and engagement in care.
The evaluation phase will include both quantitative and qualitative approaches to assess implementation and clinical outcomes. Quantitative data will be collected through structured questionnaires and clinical assessments to evaluate PrEP uptake, adherence, persistence, and HIV incidence, as well as the acceptability and feasibility of the intervention. Qualitative data from follow-up focus groups will provide insights into participants' experiences and perceptions of community-based PrEP delivery models.
The primary objective is to assess the feasibility and acceptability of delivering PrEP in community-based settings. Secondary objectives include evaluating engagement with telehealth and digital tools, identifying barriers and facilitators to PrEP use, and assessing HIV and sexually transmitted infection (STI) outcomes in the study population. The findings are expected to inform scalable strategies to improve equitable access to HIV prevention services in settings with significant social and structural inequalities.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Beatriz Grinsztejn
- Numero di telefono: +55 2138659128
- Email: beatriz.grinsztejn@gmail.com
Luoghi di studio
-
-
Rio de Janeiro
-
Nova Iguaçu, Rio de Janeiro, Brasile, 26030-380
- Reclutamento
- Hospital Geral de Nova Iguaçu
-
Contatto:
- José Henrique Pilotto, PhD
- Email: pilotto@uninet.com.br
-
Rio de Janeiro, Rio de Janeiro, Brasile, 21040360
- Reclutamento
- Instituto Nacional de Infectologia Evandro Chagas
-
Contatto:
- Emilia Jalil, PhD
- Numero di telefono: 55 2138659128
- Email: emiliajalil@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Individuals aged 15 years or older
- Gay, bisexual, and other men who have sex with men (MSM)
- Transgender women and travestis
- Other sexual and gender minorities (SGM)
- Cisgender women in situations of social or economic vulnerability
- Sex workers
- Individuals seeking HIV testing and/or pre-exposure prophylaxis (PrEP)
- HIV-negative at screening
- Willing and interested in initiating PrEP
- Eligible for PrEP according to Brazilian national guidelines
Exclusion Criteria:
- Positive HIV test result at screening or during study participation
- Individuals not eligible for PrEP according to Brazilian national guidelines
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Community-Based PrEP Delivery
Participants will receive HIV prevention services through a community-based delivery model, including HIV testing, counseling, and initiation of daily oral pre-exposure prophylaxis (PrEP) according to national guidelines.
Services will be provided in non-traditional settings, such as non-governmental organizations and mobile health units, with additional support through telehealth and mobile health (mHealth) strategies to enhance engagement, adherence, and retention in care.
Participants diagnosed with HIV during screening or follow-up will be referred for treatment within the public health system.
|
Participants will receive daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in accordance with Brazilian national guidelines for HIV prevention.
PrEP will be offered to eligible individuals who test HIV-negative at enrollment and during follow-up, with clinical monitoring and counseling provided as part of routine care.
Participants will receive HIV prevention services through community-based delivery strategies designed to reduce barriers to access.
These include provision of services in non-traditional settings such as non-governmental organizations and mobile health units, with on-site HIV testing, counseling, and same-day PrEP initiation by trained healthcare staff.
Participants will have access to telehealth consultations and mobile health (mHealth) interventions to support engagement in care, adherence to PrEP, and retention in follow-up.
These strategies may include remote clinical support, digital communication tools, and tailored adherence support interventions.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Feasibility of Community-Based PrEP Delivery
Lasso di tempo: Up to 12 months
|
Feasibility will be assessed by the proportion of planned community-based PrEP service delivery activities successfully implemented.
Indicators will include: (1) number of community-based sites activated, (2) number of individuals screened for HIV, and (3) number of participants initiating PrEP.
Results will be summarized using counts and proportions.
|
Up to 12 months
|
|
Acceptability of Community-Based PrEP Delivery
Lasso di tempo: Up to 12 months
|
Acceptability will be assessed using participant-reported outcomes collected through a structured acceptability questionnaire with Likert-scale items.
Scores will range from 1 to 5, with higher scores indicating greater acceptability of the intervention.
|
Up to 12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
PrEP Uptake
Lasso di tempo: Up to 12 months
|
Proportion of eligible participants who initiate PrEP after HIV testing and counseling in community-based settings.
|
Up to 12 months
|
|
PrEP Persistence (Retention in PrEP Care)
Lasso di tempo: Up to 12 months
|
Proportion of participants who remain engaged in PrEP care over time, including continued use of PrEP and attendance at follow-up visits.
|
Up to 12 months
|
|
HIV Incidence
Lasso di tempo: Up to 12 months
|
Number of new HIV infections diagnosed among study participants during the follow-up period.
|
Up to 12 months
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Infezioni a trasmissione ematica
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema immunitario
- Infezioni
- Infezioni da virus a RNA
- Malattie virali
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Sindromi da deficit immunologico
- Infezioni da HIV
- Amministrazione dei servizi sanitari
- Consegna dell'assistenza sanitaria
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Acidi nucleici, nucleotidi e nucleosidi
- Sanità pubblica
- Ambiente e salute pubblica
- Purine
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Servizi sanitari
- Force di lavoro e servizi per le strutture sanitarie
- Servizi sanitari preventivi
- Composti organofosfori
- Nucleosidi
- Deossiribonucleosidi
- Organofosfonati
- Adenina
- Pratica sanitaria pubblica
- Gestione dell'assistenza al paziente
- Prevenzione primaria
- Tenofovir
- Emtricitabina
- Telemedicina
- Profilassi pre-esposizione
Altri numeri di identificazione dello studio
- 84111624.4.1001.5262
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezioni da HIV
-
Federal University of São PauloGilead SciencesCompletato
-
University of MinnesotaRitiratoInfezioni da HIV | HIV/AIDS | HIV | AIDS | Problema di Aids/Hiv | AIDS e infezioniStati Uniti
-
National Institute of Allergy and Infectious Diseases...Duke University; Department of Health and Human Services (HHS)Non ancora reclutamento
-
Jecho Biopharmaceuticals Co., Ltd.Non ancora reclutamento
-
Boston UniversityBill and Melinda Gates Foundation; HE2RO, University of the WitwatersrandReclutamento
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH); Department of Health and Human ServicesReclutamento
-
University of California, Los AngelesNational Institute of Mental Health (NIMH); Partners in Hope, Inc.Reclutamento
-
Kelley-Ross & Associates, Inc.Gilead SciencesAttivo, non reclutante
-
Center for Innovative Public Health ResearchNational Institute of Mental Health (NIMH); Makerere University; Internet Solutions...Non ancora reclutamento
Prove cliniche su Oral Pre-Exposure Prophylaxis (PrEP) (Tenofovir Disoproxil Fumarate/Emtricitabine)
-
LVCT HealthLondon School of Hygiene and Tropical Medicine; Imperial College London; Bill and... e altri collaboratoriSconosciuto
-
New York UniversityUniversity of Nairobi; Impact Research & Development OrganizationCompletatoHIV | Comportamento adolescenziale | GenereStati Uniti, Kenya
-
Brigham and Women's HospitalThe Fenway InstituteCompletatoInfezione da HIV | Aderenza, Farmaco | Terapia antiretrovirale | Aderenza, trattamento | Profilassi pre-esposizioneStati Uniti
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)ReclutamentoUso di sostanze | Uso di alcol, non specificato | Comportamento sessualeStati Uniti
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Center for AIDS...CompletatoEpatite C | HIV | Disturbo da uso di oppioidi | Uso di oppioidi | Riduzione del rischioStati Uniti